SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$13.09
+1.47%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.94
From 52W high−47.95%
Volume2.19M
Market cap$1.17B
P/E (TTM)—
P/S (TTM)4.6x
Div yield—
Key dataOct 19, 2026
Open
$12.94
From 52W high
−47.95%
Volume
2.19M
Market cap
$1.17B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.9x
P/E (TTM)
—
RSI (14)
23.0
MomentumView details →
1D Return
+1.47%
YTD Return
−37.39%
SummaryUpdated Jun 1, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Waltham, Massachusetts. The company went public in March 2016 and has evolved from a research-focused organization into a commercial-stage company with two FDA-approved products launched in 2024. Syndax specializes in developing novel therapies for cancer treatment, with particular expertise in targeting specific protein interactions and immune system pathways that drive tumor growth and resistance to treatment.
Similar companies
Latest newsMore news →
Syndax Pharmaceuticals Inc shares fell 16%.5d agoSyndax Pharmaceuticals Inc shares fell more than 11% after its Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis.6d agoSyndax Pharmaceuticals Inc said it would not continue developing axatilimab for idiopathic pulmonary fibrosis.6d ago